Addressing Tamoxifen-Related Weight Achieve: Lifestyle and Pharmacotherapy Choices

CURRENT GUIDELINES

Professional organizations supply steerage on weight administration in most cancers survivors, outlining when to provoke life-style interventions and think about pharmacologic therapy. The American Cancer Society’s 2024 Nutrition and Physical Activity Guidelines advocate lifestyle-based methods as the first strategy to weight administration in most cancers survivors, with an emphasis on vitamin, bodily exercise, and behavioral assist. The American Society of Clinical Oncology (ASCO) recommends contemplating pharmacologic therapy for people with a BMI of 30 kg/m² or increased, or 27 kg/m² or increased when accompanied by obesity-related comorbidities (Ligibel et al., 2022). Similarly, the Obesity Medicine Association helps the early use of FDA-approved anti-obesity drugs for sufferers assembly these BMI thresholds, together with life-style modifications (Tondt et al., 2023). Both the ASCO and OMA emphasize that BMI ought to be used as a screening instrument as metabolic, behavioral, and social determinants modify danger at any BMI worth. Treatment targets usually embody a clinically significant weight lack of at the least 5% of complete physique weight, with the OMA recommending reassessment of pharmacologic therapy at 3 months and continuation, if at the least 5% weight reduction is achieved.

PHARMACOLOGIC OPTIONS

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), akin to semaglutide 2.4 mg (Wegovy) and liraglutide 3.0 mg (Saxenda), improve insulin secretion, delay gastric emptying, and promote satiety, resulting in decreased urge for food (Table 1). In scientific trials, semaglutide has been related to common weight reductions of roughly 15% of baseline physique weight over 68 weeks, whereas liraglutide has produced reductions of roughly 5% to eight% over 56 weeks (Rubino et al., 2022). Common uncomfortable side effects embody nausea (reported in roughly 30% to 50% of sufferers), vomiting (5% to fifteen%), diarrhea (10% to twenty%), and constipation (round 10%; Rubino et al., 2022). These gastrointestinal signs might exacerbate tamoxifen-related discomfort in some sufferers. Fatigue and dehydration can happen as secondary results of persistent gastrointestinal uncomfortable side effects. Although gastrointestinal opposed results are widespread, they’re usually gentle, dose-dependent, and have a tendency to enhance after the dose escalation interval. Less widespread however severe opposed occasions embody pancreatitis (lower than 1%) and gallbladder illness (roughly 1% to 2%; Rubino et al., 2022).

The long-term security of GLP-1 receptor agonists in people with energetic or prior most cancers stays unclear. In the Satiety and Clinical Adiposity Liraglutide Evidence (SCALE) trial, a better incidence of breast most cancers was noticed within the liraglutide group in contrast with placebo, though this distinction was not statistically important (Pi-Sunyer et al., 2015). A scientific assessment and meta-analysis by Nagendra et al. (2023), which examined 37 randomized managed trials, discovered no statistically important enhance in total most cancers danger amongst GLP-1 customers, together with no particular affiliation with breast most cancers. However, most included trials had been of restricted period and never powered to detect malignancies. More lately, Wang et al. (2024) carried out a big retrospective, multi-center cohort research involving over 1.6 million adults with sort 2 diabetes and no prior historical past of obesity-related cancers. This research discovered no important distinction in breast most cancers danger between these handled with GLP-1 receptor agonists and people handled with insulin (Wang et al., 2024). Data stay inadequate to totally assess long-term most cancers danger.

Tirzepatide (Zepbound), a twin glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA, was FDA-approved in November 2023 for persistent weight administration (U.S. Food and Drug Administration, 2023). GIP is an incretin hormone that stimulates insulin secretion in a glucose-dependent method and will improve the metabolic results of GLP-1 when mixed in twin agonist therapies. In the SURMOUNT trials, tirzepatide produced a 15% to 22% complete physique weight discount over 72 weeks (Jastreboff et al., 2022). Like GLP-1 receptor agonists, tirzepatide’s uncomfortable side effects are predominantly gastrointestinal, with nausea, vomiting, diarrhea, constipation, and stomach discomfort generally reported, affecting as much as 70% of sufferers, particularly throughout dose escalation (Jastreboff et al., 2022). Tirzepatide has demonstrated larger weight-loss efficacy and a extra favorable gastrointestinal side-effect profile in contrast with earlier GLP-1 receptor agonists in scientific trials. It has no recognized interplay with tamoxifen. Its long-term security in hormone-sensitive cancers stays unknown.

Phentermine-topiramate (Qsymia) is a mixture drug used for persistent weight administration. Phentermine, a sympathomimetic amine, suppresses urge for food by growing the discharge of norepinephrine within the hypothalamus, whereas topiramate, an anticonvulsant, promotes weight reduction by enhancing satiety and growing vitality expenditure (Gadde et al., 2011). In scientific trials, this mix has resulted in common weight lack of 8% to 10% of complete physique weight over 56 weeks (Gadde et al., 2011). Phentermine is metabolized via the CYP3A4 pathway, much like tamoxifen. While there isn’t any recognized interplay between the 2 drugs, this shared pathway might warrant warning. Reported uncomfortable side effects embody dry mouth, constipation, insomnia, paresthesia, and dysgeusia (Gadde et al., 2011). Potential severe opposed results embody elevated coronary heart price, elevated blood stress, cognitive impairment, and kidney stones (Gadde et al., 2011). Topiramate has been related to neuropsychiatric uncomfortable side effects, together with temper disturbances, nervousness, and cognitive slowing (Gadde et al., 2011).

Bupropion, an antidepressant, and naltrexone, an opioid receptor antagonist, are mixed in a single medicine, Contrave, to cut back urge for food and meals cravings by modulating the mind’s reward and stress pathways (Apovian et al., 2015). This mixture is believed to advertise weight reduction by lowering hedonic consuming and bettering emotional regulation, which can be significantly useful in managing the psychological points of weight achieve akin to melancholy and emotional consuming (Apovian et al., 2015). Clinical trials report common weight lack of 5% to 7% of baseline physique weight over 56 weeks (Apovian et al., 2015). Side results embody nausea, constipation, headache, dizziness, dry mouth, and insomnia. Naltrexone uncomfortable side effects embody nausea or constipation (Apovian et al., 2015). Because this medicine can have an effect on temper and sleep, it ought to be used cautiously in sufferers with melancholy, fatigue, or sleep issues, together with these associated to tamoxifen.

Orlistat, a gastrointestinal lipase inhibitor, reduces dietary fats absorption (Apovian et al., 2015). In scientific trials, common weight reduction with orlistat has been reported as roughly 3% to five% of baseline physique weight over 52 weeks (Apovian et al., 2015). Orlistat’s commonest uncomfortable side effects are gastrointestinal, together with diarrhea and oily stools (Apovian et al., 2015). Orlistat can cut back the absorption of fat-soluble nutritional vitamins (A, D, E, Ok), and warning ought to be used for these in danger for bone loss (Apovian et al., 2015).

CLINICAL PRACTICE IMPLICATIONS

For ladies struggling to handle tamoxifen-associated weight achieve regardless of life-style interventions, adjunctive pharmacotherapy might warrant consideration as a part of a patient-centered care plan. Weight administration recommendation ought to acknowledge the physiological challenges of tamoxifen-related weight achieve to keep away from reinforcing blame or disgrace in survivorship care. In a spotlight group, findings emphasize the significance of clear, person-centered communication about weight and weight administration, as ladies expressed a want to be seen as people somewhat than being supplied generalized recommendation (Nyrop et al., 2021). This reinforces the necessity for tailor-made, respectful discussions in survivorship care, significantly when addressing tamoxifen-associated weight achieve.

Lifestyle interventions stay the cornerstone of survivorship care for ladies receiving tamoxifen. The 2024 American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors advocate a weight loss plan wealthy in greens, fruits, complete grains, legumes (significantly soy), and fiber, whereas limiting saturated fat. Additionally, the ACS recommends partaking in 150 to 300 minutes of moderate-intensity cardio exercise per week, akin to brisk strolling, swimming, or biking, or 75 to 150 minutes of vigorous-intensity exercise (Rock et al., 2022). In addition, power coaching is beneficial at the least twice weekly to have interaction main muscle teams (Rock et al., 2022). Resistance-based train helps mitigate tamoxifen-associated muscle loss, protect bone density, and cut back the danger of sarcopenia (Rock et al., 2022). These actions enhance insulin sensitivity, which can assist counteract tamoxifen-related metabolic adjustments (Jones & Parker, 2022). Although life-style interventions stay foundational, real-world adherence might be restricted by tamoxifen-induced fatigue, emotional misery, and metabolic adjustments that complicate weight reduction efforts. For ladies unable to attain significant weight management via life-style intervention alone, adjunctive pharmacotherapy might warrant consideration as a part of individualized, patient-centered survivorship care.

Advanced practitioners (APs) play a vital position in mitigating tamoxifen-associated weight achieve and supporting survivorship care. Routine screening for weight change ought to be built-in into follow-up visits, permitting clinicians to establish early traits and intervene proactively. Additionally, APs are well-positioned to normalize conversations about weight achieve, lowering stigma and serving to survivors perceive the metabolic results of endocrine remedy. When clinically acceptable, APs ought to consider and provoke anti-obesity drugs utilizing present tips to tailor therapy to particular person danger profiles. Because protection for anti-obesity GLP-1 therapies is inconsistent throughout payers and out-of-pocket prices can exceed $1,000 per thirty days, significantly for these insured by Medicaid or high-deductible plans, APs may also function advocates, navigating prior authorizations and interesting denials when mandatory (Williams et al., 2024). Finally, efficient administration requires collaboration throughout oncology, major care, endocrine/weight problems specialists, and vitamin, making a coordinated, supportive framework that strengthens survivorship outcomes and enhances high quality of life.

CONCLUSION

Tamoxifen-associated weight achieve is a multifactorial difficulty that impacts metabolic well being and high quality of life. Lifestyle modification stays central to care. Anti-obesity drugs might supply a further instrument for sufferers who meet guideline-based standards. While the ACS emphasizes life-style modification and the ASCO and OMA define BMI-based standards for pharmacotherapy, the variation in guideline specificity round pharmacotherapy for weight administration in most cancers survivors reveals a spot in survivorship care. Advanced practitioners play an vital position in supporting weight administration for breast most cancers survivors receiving tamoxifen. Careful consideration should be given to potential interactions, uncomfortable side effects, and particular person affected person wants. Including most cancers survivors in future pharmacotherapy research can be important to constructing evidence-based suggestions. Clinical choices relating to anti-obesity drugs might contain collaboration with major care suppliers, weight problems specialists, or endocrinologists.